Kornimate/medical-research-clean huggingface dataset:
preoperative treatment of respiratory physiotherapy in lung cancer

Conditions: Lung Cancer; Physical Therapy; Thoracic Surgery; Preoperative

Summary: the home confinement caused by the covid-19 pandemic has aroused the need to use telematic communication systems to provide remote treatments. more and more research is being done on preoperative respiratory physiotherapy in patients undergoing thoracic surgery with lung cancer. it is a treatment that has great relevance in the prevention of postoperative complications and in the quality of life of the patient. therefore, this study is proposed to highlight the applicability of a telematic system of preoperative physiotherapy treatment with the fissios application at the hospital de la santa creu i sant pau (hscsp).

a pilot cohort follow-up study is proposed based on the viability of a tele-physiotherapy program preoperative respiratory thoracic surgery for pulmonary cancer. the patient selection will be done over a period of 2 months between january and february 2022, without participant limit during this period. the patient will have two face-to-face visits where the assessments and data will be collected. during follow-up patients will do 3-4 video conferencing with the principal investigator. for 3-4 weeks the patients will use the fissios app to follow up of the exercises every day. the study will be conducted at the hscsp in barcelona. the results will be analyzed by the epidemiology of the hospital de sant pau

Eligibility criteria:
inclusion criteria: * patients aged 18-\> 80 years. candidates for cp resection with curative intent, either for vats or thoracotomy, which meet the ppo-dlco\> 35% and ppo-fev1\> 35% surgical criteria, who agree to participate and sign the informed consent exclusion criteria: * patients undergoing tumor resection for cancer requiring pneumonectomy, with cognitive impairment, which are outside the area of influence of the hscsp or which do not have from an android / iphone operating system (ios) device. it is also considered an exclusion criterion not fulfilling 50% of the predefined time of the program (a week and a half) and surgical.

Keywords: lung cancer tele-physiotherapy preoperative thoracic surgery
nexavar® versus placebo in locally advanced/metastatic rai-refractory differentiated thyroid cancer

Conditions: Thyroid Neoplasms

Summary: trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

eligible subjects were randomized 1:1 to sorafenib 800 mg daily or matching placebo. progression was assessed every 8 weeks by modified recist criteria. subjects had the option to unblind study treatment after progression and to receive open label sorafenib regardless of initial treatment assignment. following discontinuation of study treatment, subjects were followed for survival every 3 months in long-term follow-up. subjects who terminated study treatment (either double only or double blind and open label) for reasons other than death, lost to follow-up or consent withdrawn entered long-term follow up

Eligibility criteria:
inclusion criteria: * locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and hurthle cell) * poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are eligible provided that the histology has no medullary differentiation nor anaplastic features * progression within 14 months (recist \[response evaluation criteria in solid tumors\] should be used as a basis for the assessment of disease progression) * rai (radioactive iodine) refractory exclusion criteria: * histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic and medullary carcinoma, lymphoma or sarcoma) * prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target vegf (vascular endothelial growth factor) or vegf receptors or other targeted agents * prior anti-cancer treatment for thyroid cancer with use of chemotherapy (low dose chemotherapy for radiosensitization is allowed) or thalidomide or any of its derivatives

Keywords: rai-refractory differentiated follicular papillary hurthle
non-technical skills training and checklists versus standard training with checklists for prevention of medical error

Conditions: Medical Emergencies

Summary: the purpose of this study is to reduce medical error by omitting management steps in medical crises. the interventions will be: training in non-technical skills and checklists versus control: standard training with checklists

56 participants will be searched for simulation training, randomly assigned in assignment 1 to 1, the follow-up will be 10 days, the primary outcome will be proportion of omissions of treatment steps per group, and secondary outcomes will be sought. crisis resolution time, detection time. and discrimination from the crisis global score of non-technical skills, discriminated score between dimensions of non-technical skills, student satisfaction and incidence of inadequate crisis management.

Eligibility criteria:
inclusion criteria: * over 18 years old. * final semester student of medicine at the university of antioquia. * have passed the theoretical knowledge exam for handling crisis events with a score of 100%. * on-site availability on training days exclusion criteria: * having received training in a specific crisis resource management course. * refusing to participate

Keywords: medical error high fidelity simulation non technical skills checklist
study of asthma and genetics in patients to be treated with fluticasone propionate/salmeterol or salmeterol xinafoate

Conditions: Asthma

Summary: this study may last up to 36-38 weeks. patients will visit the clinic 11 times. a blood sample will be taken at visit 1 to look at subjects' genes. breathing tests will be done during the study. study medicines and procedures will be provided at no cost. patients will be treated with ventolin (8 wks), atrovent (8 wks), then advair or serevent (16 wks). advair and serevent are fda approved for the treatment of asthma in patients 4 years of age and older.

a randomized, parallel group, double-blind, comparative trial assessing lung function and other measures of asthma control in adults and adolescents, at least 12 years of age, with persistent asthma, who have either a b16-arg/arg, a b16-gly/gly or a b-16 arg/gly genotype and are treated with fluticasone propionate/salmeterol diskus™ combination product 100/50mcg or salmeterol diskus 50 mcg bid

Eligibility criteria:
inclusion criteria: * diagnosis of persistent asthma for 3 months. * use of short-acting beta-agonist medication like ventolin. exclusion criteria: * hospitalization for asthma 6 months before study. * other serious diseases like congestive heart failure, uncontrolled hypertension, tb. * current use of inhaled or oral corticosteroids.

Keywords: genotype salmeterol advair
transcranial infrared laser stimulation (tils) of prefrontal cognition in post-traumatic stress disorder (ptsd)

Conditions: Post-traumatic Stress Disorder (PTSD)

Summary: this study evaluates the effects of transcranial infrared laser stimulation (tils) on prefrontal metabolism and hemodynamics in veterans with post-traumatic stress disorder (ptsd). the subjects will receive six tils interventions and one sham intervention in a course of seven weeks.

post-traumatic stress disorder (ptsd) is often associated with cognitive impairments. it has been indicated that hypoactivity of the prefrontal cortex plays a major role in the disrupted neural circuitry of mood and cognition. transcranial infrared laser stimulation (tils) is a neural type of photobiomodulation that can elevate neuronal metabolism by exciting cytochrome c oxidase (cco). veterans with ptsd will receive prefrontal tils interventions once-per-week for six weeks. they will also receive an additional sham intervention (laser power = 0) that will be randomly assigned into the first two sessions. broadband near-infrared spectroscopy (bbnirs) will be used to directly assess the cco changes during every tils/sham session. veterans' prefrontal functions will be evaluated with short-term memory tasks before and after each intervention. the prefrontal activities will also be imaged by functional near-infrared spectroscopy (fnirs) to objectively assess the functional changes due to tils/sham interventions.

Eligibility criteria:
inclusion criteria: * war-zone and non-war-zone veterans * ages 18-60 years old * males and females * able to read, speak, and understand english * medical records showing prior diagnosis of ptsd (here it refers to the records prior to tils, which will be assessed and obtained in visit 1) * medical records showing diagnosis of ptsd (here it refers to the caps-5 record prior to tils, which will be assessed and obtained in visit 1) * on stable doses of any psychotropic medications for at least 4 weeks exclusion criteria: * significant physical disability to perform a computerized memory task * past/current significant medical/neurological/mental health disorders known to affect cognitive functioning (e.g., stroke, dementia, schizophrenia, aids) * presence of moderate/severe tbi, defined as having: alteration of consciousness/mental state \>24 hours; posttraumatic amnesia \>1 day; loss of consciousness \>30 minutes; and/or abnormal structural neuroimaging. we will not exclude veterans with mild tbi, which is found in nearly 50% of veterans with ptsd * alcohol abuse/dependence for the past 12- months, as determined by the rapid alcohol problems screen score \>0 * drug abuse/dependence for the past 12- months, as determined by the drug abuse screening test-10 score \>2 * severe depression (phq-9 total score \>19), significant risk of suicide (sbq-r \>6), severe headache (phq-15, item e =2), and/or severe dizziness (phq-15, item g =2) * opiate use in the month prior to study entry

Keywords: transcranial infrared laser stimulation (tils) near-infrared spectroscopy (nirs)
myocardial ischemia and transfusion pilot

Conditions: Myocardial Infarction; Unstable Angina; Coronary Artery Disease

Summary: the purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.

red blood cell transfusions are extremely common medical interventions, yet, it remains unclear when patients should be transfused. this pilot study will evaluate the feasibility of conducting a research protocol that will lead to a large scale clinical trial designed to evaluate the treatment effectiveness of two transfusion threshold strategies in patients with coronary artery disease.

Eligibility criteria:
inclusion criteria: * age 18 or older; * stemi (st segment elevated myocardial infarction) * nstemi (non st segment elevation myocardial infarction) * unstable angina * stable coronary artery disease (undergoing cardiac catheterization during the index hospitalization); * written informed consent has been obtained * hemoglobin concentration less than 10 g/dl at the time of random allocation. exclusion criteria: * bleeding cannot be controlled at the cardiac catheterization puncture site and/or require surgery to repair vessel * retroperitoneal bleeding requiring surgery * clinically important hemodynamic instability based on the judgment of the treating physician * terminal malignancy or life expectancy less than 6 months * scheduled for cardiac surgery within the next 30 days * symptomatic at the time of randomization * declines blood transfusion * history of a clinically significant transfusion reaction * inability to provide informed consent; * enrolled in a competing study * previous participation in the mint trial * any patient who in the judgment of the research team should not be enrolled in the trial. this would include, but not be limited to, factors such alcohol or drug dependence, or psychiatric illness.

Keywords: blood transfusion red blood cell transfusion myocardial infarction acute coronary syndrome anemia
tailored information about the coronavirus for patients with chronic kidney disease

Conditions: Renal Insufficiency, Chronic

Summary: randomized clinical trial focusing on the effect of tailored information on covid-19 for patients with chronic kidney disease stage 5 on health literacy, anxiety and self-perceived health.

this single-center randomized open clinical trial in persons with chronic kidney disease stage 5 investigates the effect of information about coronavirus targeted at the study population, using study specific information videos followed by a teach-back method. we measure digital, functional, interactive and critical health literacy, fear of coronavirus and self-perceived health at baseline and end-of-study. patients are followed from may-july 2021 through february 2022 (study period 7-9 months).

Eligibility criteria:
inclusion criteria: * chronic kidney disease stage 5 exclusion criteria: * covid-19 during last 12 months. dementia or other reason why cannot participate like major depression, psychosis or hospitalized persons with severe frailty.

Keywords: digital health literacy health literacy fear of coronavirus self-perceived health teach-back
effect of chemotherapy on pain sensitivity and patient-reported symptoms

Conditions: Breast Cancer; Chronic Pain

Summary: many breast cancer survivors report chronic pain that develops or worsens following chemotherapy. the impact of chemotherapy on the development of chronic pain is uncertain. in this proposal, we are studying the impact of chemotherapy on a patient's sensitivity to pain. we are also investigating whether a patient's sensitivity to pain is related to how many symptoms she experiences during treatment.


Eligibility criteria:
inclusion criteria: * female gender * histologically proven stage i-iii invasive carcinoma of the breast who is planning to receive a standard dose of adjuvant chemotherapy. * surgical resection should be complete at the time of study enrollment. * eastern cooperative oncology group performance status 0-2. exclusion criteria: * average pain over the past 24 hours of 4 or greater on a 0-10 scale. * peripheral sensory neuropathy grade 2 or higher. * personal history of schizophrenia or major depressive disorder, or history of suicidal ideation or attempt within the past 2 years. * thumbnail abnormalities on either hand (such as artificial nails) that are likely to alter pain perception during testing. * pregnant or nursing. * no prior chemotherapy for any reason

Keywords: breast cancer chemotherapy chronic pain survivorship
fos immunohistochemical staining of colorectal cancer and its adjacent tissues

Conditions: Colorectal Cancer; Monkey Pox

Summary: colorectal cancer tissue sections were obtained according to the inclusion criteria. the formalin was used to immersed all cancer specimens. and tissues were cut to 5 μm thickness and placed on glass slides before staining. endogenous peroxidase activity was inhibited and blocked by de-paraffinizing, rehydrating, and using 5% bovine serum albumin at 37ºc for 30 min. the treated sections were incubated with anti-fos (promab 30360) at 4ºc overnight and washed three times with pbs. after that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºc for 30 minutes. after washing three times again with pbs, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.


Eligibility criteria:
inclusion criteria: * (a) patients with histologically confirmed crc (b) patients who underwent resection of the primary tumor (c) patients at first visit who had not received treatment before blood testing. exclusion criteria: * (a) familial adenomatous polyposis or hereditary colon cancer (b) no signs of clinical infection, such as fever, on the day of blood collection; and (c) patients with multiple primary tumors during hospitalization.

Keywords: differential expression of gene immunohistochemical staining tumor microenvironment
healthcare utilization in liver cirrhosis patients, a multicenter retrospective cohort study

Conditions: Liver Cirrhosis

Summary: multicenter, retrospective cohort study investigating healthcare utilization in compensated and decompensated liver cirrhosis patients, including disease course and characteristics associated with healthcare utilization and, for example psychosocial factors.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age * liver cirrhosis, based on biopsy, fibroscan or diagnostic imaging data exclusion criteria: * known malignancy with hepatic metastasis at baseline * liver transplantation at baseline
a phase iii study of pa21 in peritoneal dialysis patients with hyperphosphatemia

Conditions: Peritoneal Dialysis; Hyperphosphatemia

Summary: the purpose of this study is to investigate efficacy and safety, when administering pa21, in peritoneal dialysis patients having hyperphosphatemia.


Eligibility criteria:
inclusion criteria: * receiving stable maintenance peritoneal dialysis * peritoneal dialysis patients with hyperphosphatemia exclusion criteria: * patients having history of a pronounced brain / cardiovascular disorder * patients having severe gastrointestinal disorders * patients having severe hepatic disorders

Keywords: peritoneal dialysis hyperphosphatemia
mirabegron, propevirine, solifenacin for treatment of lower urinary tract symptoms during intravesical bcg instillation

Conditions: Voiding Disorders

Summary: a randomized controlled study to compare the efficacy of mirabegron, solifenacin and propevirine for treatment of lower urinary tract symptoms during intravesical bcg installation


Eligibility criteria:
inclusion criteria: * patients older than age 18 years. * able to provide an informed consent. * denovo or recurrent cases with intermediate and high risk nmibc eligible for intravesical bcg immunotherapy. * persistent luts after intravesical bcg induction. exclusion criteria: * international prostate symptom score (ipss) greater than 20. * post-void residual (pvr) volume greater than 50 ml. * use of medications for overactive bladder. * pelvic surgery within the previous 6 months. * hypersensitivity for bcg or any of the above mentioned drugs. * tumor recurrence during follow up period. * other medical conditions that would be adversely affected by anticholinergics such as history of urinary retention due to bph(benign prostatic hyperplasia), constipation and history of narrow angle glaucoma.
short-term clinical outcome of total hip arthroplasty using larger diameter of 4th generation ceramic bearing

Conditions: Arthropathy of Hip

Summary: the primary objectives of this clinical study include: * assess the rate of dislocation and fracture of tha using the new (the 4th generation) ceramic implants. * evaluate the survival rate of tha using the new alumina-zirconia (the 4th generation) composite ceramic bearing. * investigate the performance of the 4th generation ceramic implants mostly in patients younger than 50 years. * compare the preoperative and postoperative scores of harris hip score, ucla activity score and womac.

this study will evaluate incidence of dislocation and short-term clinical outcome on patients who undergo large diameter 4th generation ceramic bearing total hip arthroplasty ("tha") in comparison to historical data on 3rd generation coc tha (28mm) patients. specifically the study intends to address the following research topics: 1. the incidence of dislocation after tha with use of the 4th generation ceramic bearing in comparison to 3rd generation ceramic bearing. 2. the incidence of ceramic fracture after tha with use of the 4th generation ceramic bearing in comparison to 3rd generation ceramic bearing 3. the survival rate, wear rate, and incidence of osteolysis of tha with use of the 4th generation ceramic bearing 4. range of motion improvement from preoperative to postoperative to support korean sitting style after tha with use of the 4th generation ceramic bearing. 5. clinical outcomes, activity level and qol of patients with use of the 4th generation ceramic bearing. 6. the performance of tha with use of the new ceramic bearing mostly in patients younger than 50 years.

Eligibility criteria:
inclusion criteria: * patients suitable for primary total hip replacement * patients with degenerative joint disease (inflammatory or non-inflammatory) or any of the composite diagnoses of: 1. osteoarthritis 2. avascular necrosis 3. legg perthes 4. rheumatoid arthritis 5. diastrophic variant 6. fracture of the pelvis 7. fused hip 8. slipped capital epiphysis 9. subcapital fractures 10. traumatic arthritis * patients aged over 20 * patients must be able to understand instructions and be willing to return for follow-up exclusion criteria: * absolute contraindications include: infection, sepsis, and osteomyelitis * relative contraindications include: 1. uncooperative patient or patient with neurologic disorders who are incapable of following directions, 2. osteoporosis, 3. metabolic disorders which may impair bone formation, 4. osteomalacia, 5. distant foci of infections which may spread to the implant site, 6. rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram, and 7. vascular insufficiency, muscular atrophy, or neuromuscular disease. 8. pregnancy
cied implantation in low bmi patients

Conditions: Heart Diseases; Cardiac Disease

Summary: the primary objective is to demonstrate a better degree of healing at the incision site and a decrease in erosion with cangaroo compared to control patients (no envelope, cied alone).

a single-center, prospective, randomized, post-market study of patients undergoing implantation of a pacemaker, icd, or s-icd with or without cangaroo using the same hydration solution. twenty patients, randomized 1:1 for 10 in the treatment group and 10 in the control group, shall be enrolled. follow-up visits include post-op and 3-months following the implantation procedure.

Eligibility criteria:
inclusion criteria: * bmi of less than 23. * already scheduled for or a clinical decision made to have one of the following qualifying cied implant procedures using a device cleared by the u.s. fda: * de novo pacemaker, icd, or s-icd; * upgrade or change out of existing cied to a pacemaker, icd, or s-icd * clinically stable and able to tolerate procedure. * be able and willing to return for follow-up care through the 3-month visit. * must possess the ability to provide informed consent. exclusion criteria: * patients with a known sensitivity to porcine material. * participation in another clinical study. * active infection. clinical diagnosis of an active infection at the time of cied implant (cied infection, pneumonia, uti, endovascular, cellulitis, bacteremia, or other major systemic infection). * female patient who is pregnant, or planning to become pregnant during the length of the study. * prior history of a cied infection, other prosthetic device infection, or endovascular infection, including endocarditis in the past 12 months. * life expectancy of less than 3 months.

Keywords: cied, pacemaker, icd, s-icd